Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444203 · ClinicalTrials.gov registry record
Transformative Research in Diabetic Nephropathy 2.0
A clinical trial of Diabetes Mellitus, Type 2 and Kidney Diseases, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07444203 is a study of Diabetes Mellitus, Type 2 and Kidney Diseases that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 200 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07444203, a study of Diabetes Mellitus, Type 2 and Kidney Diseases, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
Conditions Studied
Interventions
- DRUG Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
- DRUG Renin-angiotensin-aldosterone system blockade
- DRUG Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- DRUG Mineralocorticoid Receptor Antagonists(MRAs)
Study Locations (1)
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-11-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07444203
The ClinicalTrials.gov registry entry for NCT07444203 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first listed.
NCT07444203 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07444203 about?
NCT07444203 is a clinical study titled "Transformative Research in Diabetic Nephropathy 2.0". The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect...
What is the current status of trial NCT07444203?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-11-12. Estimated completion is 2028-11-12.
What conditions does trial NCT07444203 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Kidney Diseases, Renal Insufficiency, Chronic, Diabetic Nephropathies.
What interventions are being tested in trial NCT07444203?
The interventions under investigation include: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (DRUG), Renin-angiotensin-aldosterone system blockade (DRUG), Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (DRUG), Mineralocorticoid Receptor Antagonists(MRAs) (DRUG).
Who is sponsoring clinical trial NCT07444203?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07444203 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.